Trial Profile
A study investigating bortezomib efficacy against acute antibody mediated rejection (AAMR) in patients undergoing kidney transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab
- Indications Transplant rejection
- Focus Therapeutic Use
- 07 Dec 2015 New trial record